Meeting
2012 Gastrointestinal Cancers Symposium
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
Authors
Li-Tzong Chen
National Health Research Institutes, Tainan, Taiwan
Li-Tzong Chen , Her-Shyong Shiah , Peng-Chan Lin , Jenq-Chang Lee , Wu-Chou Su , Yi-Wen Wang , Grace Yeh , Jang-Yang Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00940758
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 613)
DOI
10.1200/jco.2012.30.4_suppl.613
Abstract #
613
Poster Bd #
E44
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.
First Author: Eric Roeland
Poster
2018 Gastrointestinal Cancers Symposium
A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.
First Author: Shigenori Kadowaki
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz